Neuromed IRCCS   Report issue

Academic/Hospital Phase 1
Founded: Pozzilli Italy (1976)

Organization Overview

First Clinical Trial
2017
NCT03228524
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

IRCCS Neuromed | Neuromed IRCCS

Active Ingredients

Drugs in Phase 1 Trials (1)

d-aspartate (1 trial)

Drugs in Other Trials (2)

levodopa (larodopa) (1 trial)

ozonated oil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3